8-K: Turnstone Biologics Announces Positive Phase 1 Trial Results and Second Quarter 2024 Financials

Turnstone Biologics reported positive initial data from its Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, including a complete response in one patient, and announced its second quarter 2024 financial results.

Summary

• Turnstone Biologics announced financial results for the second quarter of 2024, ending June 30, 2024.
• The company reported positive initial data from its Phase 1 trial of TIDAL-01 in metastatic colorectal cancer.
• The trial showed a 25% overall response rate (ORR) and a 50% disease control rate (DCR) in the first four evaluable patients.
• One patient achieved a complete response (CR) and has remained progression-free for over one year.
• The company's cash position is expected to fund operations into the third quarter of 2025.
• Research and development expenses for the quarter were $17.7 million, compared to $17.2 million in the same period of 2023.
• General and administrative expenses were $4.3 million, down from $4.7 million in the same period of 2023.
• The net loss for the quarter was $21.3 million, compared to a net loss of $21.5 million for the same period in 2023.
• The company is prioritizing the development of TIDAL-01 in solid tumor indications, including metastatic colorectal cancer, head and neck cancer, and uveal melanoma.
• Turnstone has deprioritized cutaneous melanoma and breast cancer in its clinical development strategy.
• The manufacturing success rate for TIDAL-01 in colorectal cancer was 80%.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strong cash position, which are favorable for investors. The company is also focusing on high unmet medical need indications. However, the company is still in the clinical stage and faces risks associated with drug development.

Positives

• The initial data from the TIDAL-01 trial shows promising clinical activity, including a complete response in one patient.
• The 25% ORR and 50% DCR are significantly better than the current standard of care for this patient population, which has an ORR of 1-6%.
• The company has a strong cash position that is expected to fund operations into the third quarter of 2025.
• TIDAL-01 has demonstrated a favorable tolerability profile.
• The company has achieved consistent manufacturing success with TIDAL-01.
• The company is focusing on high unmet medical need indications.

Negatives

• The company reported a net loss of $21.3 million for the second quarter of 2024.
• Research and development expenses increased slightly compared to the same period in 2023.
• The company has deprioritized development in cutaneous melanoma and breast cancer.

Risks

• The company's product candidates are still under clinical study and have not yet been approved for marketing by the U.S. Food and Drug Administration.
• There is a risk that results from clinical trials may differ from preclinical, early clinical, interim, preliminary or expected results.
• The company may need additional capital to achieve its goals.
• The company faces risks related to macroeconomic conditions and global health concerns.
• There is a risk that the company may not be able to obtain, maintain or protect intellectual property rights related to its product candidates.

Future Outlook

The company expects its current cash position to fund operations into the third quarter of 2025 and plans to continue the development of TIDAL-01 in solid tumor indications.

Management Comments

• Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer, stated that the company has continued to bolster its position by making advances across its pipeline and corporate operations.
• Sammy Farah also noted that the clinical signals from the initial data, including a complete response in one patient, support the company's hypothesis of enriching for tumor-reactive T cells in their Selected TIL therapies.
• Mike Burgess, MBChB, Ph.D., Turnstone's Interim Chief Medical Officer, stated that the early evidence of clinical benefit highlights TIDAL-01 as a potential therapeutically viable option in metastatic CRC.

Industry Context

The announcement is significant as it highlights the potential of Selected TIL therapy in treating solid tumors, particularly metastatic colorectal cancer, where current treatment options are limited and have low response rates. The results position Turnstone as a potential competitor in the oncology space.

Comparison to Industry Standards

• The reported 25% overall response rate (ORR) for TIDAL-01 in metastatic colorectal cancer is significantly higher than the 1-6% ORR typically seen with the current standard of care treatments for this patient population.
• The median progression-free survival (mPFS) for standard of care is 2.0-5.6 months, while one patient in the TIDAL-01 trial has been progression-free for over one year, indicating a potentially superior outcome.
• The manufacturing success rate of 80% for TIDAL-01 is consistent with other early clinical-stage cell therapies, suggesting a viable production process.
• Companies like Iovance Biotherapeutics are also developing TIL therapies, but Turnstone's approach of selecting and expanding the most potent tumor-reactive T cells may offer a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders may view the positive clinical trial results and strong cash position favorably.
• Employees may be encouraged by the company's progress and focus on high unmet medical needs.
• Patients with metastatic colorectal cancer may benefit from the potential of TIDAL-01 as a new treatment option.
• The company's focus on specific indications may impact suppliers and partners.

Next Steps

• Turnstone will continue to enroll patients in multiple Phase 1 trials of TIDAL-01.
• The company will continue to evaluate the benefits of TIDAL-01 in colorectal cancer and other tumor types.
• The company will advance its preclinical pipeline programs, including TIDAL-02.

Key Dates

Keywords

TIDAL-01, Selected TIL, Colorectal Cancer, Metastatic Cancer, Immunotherapy, Clinical Trial, Phase 1, Tumor-Infiltrating Lymphocytes, Oncology, Biotechnology